Drug
LU Af82422
LU Af82422: highest development phase Phase 2, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AF82422 NCT05104476 | Phase 2 | Multiple System Atrophy |
Latest
No recent events.
Follow LU Af82422 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.